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Abstract
Aims/hypothesis We sought to investigate the stimulation of
islet regeneration by transplanted human umbilical cord
blood (UCB) cells purified according to high aldehyde
dehydrogenase (ALDH) activity (ALDHhi), a conserved
characteristic of multiple progenitor lineages. We hypothesised that direct intrapancreatic (iPan) delivery of ALDHhi
progenitors would augment islet regeneration via timely and
localised exposure to islet-regenerative stimuli.
Methods Cells were purified from UCB based on flow
cytometry for low ALDH activity (ALDHlo) vs ALDHhi.
UCB ALDHlo or ALDHhi cells were compared for surface
marker expression, as well as haematopoietic, endothelial
and multipotent stromal progenitor content in vitro. UCB
ALDHlo or ALDHhi cells were i.v. or iPan injected into
streptozotocin-treated non-obese diabetic/severe combined
immune-deficient mice temporally monitored for blood
glucose, serum insulin and glucose tolerance. Human cell
recruitment and survival in the pancreas, insulin content,
islet-associated cell proliferation and islet vascularisation were
documented in situ.
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Results UCB-derived ALDHhi cells were highly enriched for
haematopoietic and endothelial progenitor frequency, and
showed increased expression of progenitor and myeloid cell
surface markers. Although i.v. transplantation of ALDHhi
cells demonstrated low pancreas engraftment and only transient blood glucose lowering capacity, iPan injected ALDHhi
cells reversed established hyperglycaemia, increased serum
insulin and improved the response to a glucose challenge.
iPan injected ALDHhi cells surrounded damaged islets at early
time points and increased islet-associated cell proliferation,
resulting in the recovery of beta cell mass.
Conclusions/interpretation iPan delivery of UCB ALDHhi
cells potentiated islet-associated cell proliferation, insulin production and islet revascularisation, resulting in the recovery of
host islet function. Elucidation of the progenitor-specific pathways stimulated during islet regeneration may provide new
approaches to promote islet expansion during diabetes.
Keywords Aldehyde dehydrogenase . Beta cell
proliferation . Cell therapy . Diabetes . Intrapancreatic
transplantation . Islet regeneration . Islet revascularisation .
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Abbreviations
ALDH
Aldehyde dehydrogenase
BM
Bone marrow
CFC
Colony-forming cell
EdU
5-Ethynyl-2′-deoxyuridine
iPan
Intra-pancreatic
NOD/SCID Non-obese diabetic/severe combined
immune-deficient
STZ
Streptozotocin
UCB
Umbilical cord blood
vWF
von Willebrand factor
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Introduction
Residual islet function in diabetes patients with disease
duration of >50 years suggests that the stimulation of islet
regeneration may represent a viable strategy for diabetes
treatment [1]. There exists increasing evidence that bone
marrow (BM)-derived cells promote islet recovery after
transplantation [2–4], and we have recently shown that the
mechanisms of islet regeneration are modulated by the progenitor subtypes administered [5]. While transplanted human multipotent stromal cells stimulated the formation of
small islets associated with ducts, i.v. transplanted BM with
high aldehyde dehydrogenase (ALDH) activity (ALDHhi)
induced islet cell proliferation and led to the recovery of
larger and highly perfused islets [5]. As a readily available
alternative to BM, we postulated that transplantation of
umbilical cord blood (UCB)-derived ALDHhi cells would
stimulate islet expansion and vascularisation. Since human
cell recruitment to the pancreas is inefficient following i.v.
transplantation [5], we intended to determine if UCB
ALDHhi cells delivered directly to the pancreas would permit timely exposure to regenerative stimuli and potentiate
the recovery of islet function.
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being killed, each mouse received 200 μg 5-ethynyl-2′deoxyuridine (EdU), and a fasted (4 h) glucose tolerance
test (2.0 g/kg glucose) was performed for a duration of 2 h.
Serum was collected for insulin ELISA (Alpco, Salem, NH,
USA). BM and pancreas were analysed for human cells by
flow cytometry as previously described [5, 7].
Immunohistochemistry Frozen pancreas sections were
stained for immunofluorescent analyses to detect murine
insulin with human cell engraftment (HLA-A,B,C), blood
vessel density (von Willebrand factor; vWF) and EdU incorporation as previously described [5].

Results
UCB ALDHhi cells possessed haematopoietic and endothelial
progenitor phenotypes and functions We first characterised
UCB ALDHlo vs ALDHhi cells for cell surface marker
expression and for haematopoietic, endothelial and multipotent stromal colony formation in vitro. Compared with
UCB ALDHlo cells that primarily expressed lymphocyte
markers, ALDHhi cells highly expressed myeloid (CD33)
and haematopoietic/endothelial progenitor markers (CD34,
CD117, CD133; see electronic supplementary material

Methods
Cell isolation and characterisation Human UCB was
obtained by venipuncture after informed consent at the
London Health Sciences Centre. Within 24 h, mononuclear
cells were isolated by Ficoll-Hypaque centrifugation, and
cells with low ALDH activity (ALDHlo), as well as ALDHhi
cells, were purified by cell sorting based on ALDH activity
using Aldefluor reagent (Stem Cell Technologies, Vancouver,
BC, Canada) as previously described [6]. ALDHlo and
ALDHhi cells were characterised for mature haematopoietic
and primitive progenitor marker expression, and colonyforming cell (CFC) assays were performed for haematopoietic, endothelial and multipotent stromal progenitor
functions as previously described [7].
Transplantation of hyperglycaemic mice Non-obese diabetic/
severe combined immune-deficient (NOD/SCID) mice
(Jackson Laboratory, Bar Harbor, ME, USA) were injected
with streptozotocin (STZ) 35 mg/kg per day i.p. on days 1–
5. At day 10, mice were sublethally irradiated (300 cGy) to
reduce residual innate immunity and transplanted by tail
vein or intrapancreatic (iPan) injection with PBS or 2×105
ALDHlo or ALDHhi cells from a fresh UCB sample. For
iPan injections, mice were anaesthetised, the pancreas and
spleen exposed, and cells were microinjected (10 μl) into
the splenic portion of the pancreas. Non-fasted blood glucose was monitored weekly. Twenty-four hours prior to

Fig. 1 iPan delivery of UCB ALDHhi cells augments the recovery of b
endocrine functions via increased islet size and vascularisation. Blood
glucose, serum insulin and glucose tolerance measurements were performed on i.v. transplanted vs iPan transplanted mice. a Compared with
mice i.v. injected with PBS (black squares, dashed line, n06) or mice i.v.
injected with 2×105 ALDHlo cells (dark grey circles, n08), mice i.v.
injected with 2×105 ALDHhi cells (light grey triangles, n09) showed a
transient reduction (days 14–21) in blood glucose that returned to hyperglycaemic levels by days 28–42. The dotted line marks hyperglycaemia
(>12 mmol/l), defined as a twofold increase from basal glucose concentrations. (*p<0.05 vs PBS). b At day 42, all i.v. transplanted mice showed
reduced serum insulin concentrations, and (c) were unable to respond to a
glucose challenge. d Mice iPan injected with 2×105 ALDHhi cells (light
grey triangles, n06) showed significantly improved blood glucose from
days 17 to 42, compared with mice iPan injected with PBS (black squares,
dashed line, n06) or ALDHlo cells (dark grey circles, n07). (*p<0.05,
***p<0.001 vs PBS). e Mice iPan injected with ALDHhi cells showed
elevated serum insulin, and (f) improved response to glucose challenge at
day 42 (*p<0.05 vs PBS). Compared with mice iPan injected with PBS
(n03) or ALDHlo cells (n04), mice iPan injected with ALDHhi cells
(n04) also showed increased (g) islet number, (h) islet size and (i) total
beta cell mass at day 42. iPan delivery of ALDHhi cells also increased islet
size and total beta cell mass compared with i.v. injected ALDHhi cells.
Representative photomicrographs of mouse pancreas stained for murine
insulin and vWF at day 42 after (j) i.v. injection or (k) iPan injection with
2×105 ALDHhi cells. Arrowheads mark vWF+ vascular structures in
islets. Scale bars, 50 μm. l Compared with mice iPan injected with PBS
or ALDHlo cells, mice iPan injected with ALDHhi cells increased islet
vascularisation at day 42. iPan delivery of ALDHhi cells also increased
islet vascularisation compared with i.v. injected ALDHhi cells. Cells from
a total of five UCB samples were used for day 42 analyses. Data are
presented as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001). A,
ALDH; CAB, citric acid buffer vehicle control
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[ESM] Table 1). In contrast to BM ALDHhi cells that possessed CFC capacity for all three-progenitor lineages [7],
UCB ALDHhi cells were enriched for multipotent haematopoietic and endothelial CFC (ESM Fig. 1a–e), but did not

iPan

establish multipotent stromal colonies (ESM Fig. 1c, f).
Thus, UCB ALDHhi cells represent a mix of early myeloid
cells and haematopoietic progenitors with endothelial progenitor content.
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iPan delivery of UCB ALDHhi cells improved endocrine
function To investigate whether direct iPan delivery of
UCB progenitors could induce islet regeneration, STZtreated NOD/SCID mice were i.v. or iPan injected with
PBS or dose-matched UCB ALDHlo or ALDHhi cells. After
i.v. transplantation of ALDHhi cells on day 10, blood glucose was transiently reduced in comparison with that of PBS
controls. However, from days 17 to 42, blood glucose gradually increased towards severe hyperglycaemia (>20 mmol/l;
Fig. 1a). Serum insulin (Fig. 1b) and response to glucose
challenge (Fig. 1c) at day 42 were low for all i.v. transplanted
groups. By contrast, iPan delivery of UCB ALDHhi cells
reduced hyperglycaemia within 7 days (*p<0.05), and blood
glucose remained lower than pretransplant levels for >1 month
(Fig. 1d), indicating immediate and stable recovery from
established hyperglycaemia. Compared with mice iPaninjected with PBS or ALDHlo cells, iPan ALDHhi transplanted
mice showed increased serum insulin (Fig. 1e) and improved
response to glucose challenge at day 42 (Fig. 1f).
iPan delivery of UCB ALDHhi cells increased islet number,
size and vascularisation We postulated that iPan delivery of
UCB ALDHhi cells would augment pancreas islet content.
Compared with delivery-matched PBS or ALDHlo cells,
iPan injection of ALDHhi cells increased both the number
and size of islets, and augmented total beta cell mass
(Fig. 1g–i). Furthermore, islet size and total beta cell mass
were increased compared with i.v. injection of ALDHhi cells
(*p<0.05). Although i.v. delivery of ALDHhi cells modestly
increased islet-associated vascularisation (Fig. 1j, l), iPan
delivery of ALDHhi cells further improved islet vascularisation (Fig. 1k, l). These effects were observed despite lowfrequency human cell engraftment in the pancreas of mice i.v.
injected (four of nine mice) or iPan injected (four of five mice)
with ALDHhi cells at day 42 (ESM Fig. 2a–b). By contrast,
ALDHlo cells were rarely detected in the pancreas after i.v. or
iPan injection. Only ALDHhi cell i.v. transplanted mice
showed haematopoietic reconstitution in the murine BM
(ESM Fig. 2c–d). Collectively, these data suggested that
further experiments were warranted to characterise islet regenerative processes in relation to human cell pancreatic
engraftment at early time points (days 14–17).
iPan-injected UCB ALDHhi cells surrounded islets and
stimulated islet cell proliferation To investigate human cell
engraftment during hyperglycaemic reduction, mouse pancreases were isolated at days 14 and 17 and stained for cells
producing insulin and HLA-A,B,C. At day 14, HLA+ cells
were very infrequent or absent in mice iPan injected with
ALDHlo cells (ESM Fig. 2e). By contrast, iPan injected
ALDHhi cells showed improved survival and HLA+ cells
were numerous throughout the pancreas (Fig. 2a). By
day 17, when insulin production was sufficient to clearly
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identify regenerating islets, iPan delivered ALDHhi cells
were localised surrounding islets (Fig. 2b). Although few
human cells remained at day 42 (arrows, Fig. 2c), HLA+
cells never produced insulin (Fig. 2a–c). At days 14 and 17,
human cell engraftment was not detected in the pancreas of
any i.v. transplanted mice (data not shown). These data
suggested that improved ALDHhi cell survival and recruitment to islets correlated with the temporal recovery of
insulin production.
Next we assessed islet-associated cell proliferation using
EdU labelling 24 h prior to sacrifice. While islet-associated
proliferation was minimal in mice iPan injected with
ALDHlo cells (ESM Fig. 2f), mice iPan injected with
ALDHhi cells demonstrated EdU labeling in both insulin−
(arrowheads) and insulin+ cells (arrows, Fig. 2d, e). By
day 17, the percentage of EdU+ cells within islets was
increased (Fig. 2f), as was the frequency of insulin+ EdU+
cells (ALDHhi 29.5±3.4% vs ALDHlo 6.3±1.2%; *p<0.05).
Corresponding to islet proliferation at early time points,
iPan ALDHhi transplanted mice showed an increase in
non-fasted serum insulin (Fig. 2g, i). However, serum insulin levels remained below threefold lower than citric acid
buffer controls. Although iPan transplanted mice did not
demonstrate a measurable response to glucose bolus at
day 14 (Fig. 2h), iPan ALDHhi transplanted mice demonstrated improved glucose tolerance by day 17 (Fig. 2j).
Collectively, these data suggested that within 4–7 days of
iPan administration, increased ALDHhi cells surrounding
islets correlated with increased proliferation of insulin+ and
insulin− cells, resulting in augmented insulin production and
improved endocrine functions.

Discussion
This study demonstrates the capacity of UCB-derived
ALDHhi cells to promote islet regeneration when transplanted directly into the murine pancreas. UCB ALDHhi
cells represented a heterogeneous mixture of myeloid cells
and haematopoietic/endothelial progenitors readily available
for the development of novel cellular therapies for type 1 or
type 2 diabetes through the recent establishment of UCB
registries for allogeneic transplantation. While i.v. transplantation of UCB ALDHhi cells leads to minimal recovery of
islet function, iPan delivery of UCB ALDHhi cells leads to
reversal of established hyperglycaemia, increased serum
insulin and improved glucose tolerance within 7 days of
transplantation. To our knowledge this work represents the
first report documenting potent islet recovery after iPan
delivery of clinically applicable progenitors isolated from
human UCB.
Islet cell proliferation correlated with the presence of
UCB ALDHhi cells surrounding damaged islets, and islet
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Fig. 2 iPan delivery of UCB ALDH cells formulates a niche for islet
regeneration. a,b Representative photomicrographs of human cell engraftment within the pancreas 4 (day 14) and 7 (day 17) days after iPan
injection of UCB ALDHhi cells. c At day 42, few HLA+ cells were
detected surrounding insulin+ islets. Arrows mark HLA-A+, -B+ and
-C+ cells. d,e Representative photomicrographs demonstrating EdU+
cells within regenerating islets at 4 (day 14) and 7 (day 17) days
following iPan injection of ALDHhi cells. Arrowheads mark insulin−/
EdU+ cells associated with islets. Arrows mark insulin+/EdU+ cells
within islets. Scale bars, 50 μm. f At day 17, mice iPan injected with
ALDHhi cells (n04) demonstrated an increased frequency of EdU+
cells within islets compared with mice iPan injected with PBS (n03) or
ALDHlo cells (n04) (*p< 0.05 vs PBS). g At day 14, mice iPan
injected with ALDHhi cells (n03) showed increased non-fasted serum
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insulin compared with mice iPan injected with PBS (n03) or ALDHlo
cells (n03). h However, at day 14, mice iPan injected with ALDHhi
cells (light grey triangles) did not respond to a glucose challenge. i At
day 17, mice iPan injected with ALDHhi cells (n04) showed increased
non-fasted serum insulin compared with mice iPan-injected with PBS
(n03) or ALDHlo cells (n04). iPan delivery of ALDHhi cells also
increased non-fasted serum insulin compared with i.v. injected
ALDHhi cells (n03). j By day 17, mice iPan injected with ALDHhi
cells (light grey triangles) demonstrated improved glucose tolerance
compared with mice iPan-injected with PBS (black, n03) or ALDHlo
cells (dark grey circles, n03) (*p<0.05 vs PBS). Cells from a total of
three UCB samples were used for day 14 and 17 analyses. Data are
represented as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001). CAB,
citric acid buffer vehicle control; A, ALDH
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number, size and vascularisation were increased 1 month
post-transplantation. Although iPan injected ALDHlo cells
were occasionally detected in the pancreas at early time
points, these cells failed to induce islet-associated proliferation and subsequent recovery of function. Thus, islet regeneration was promoted after timely local exposure to
ALDHhi cells, suggesting that islet proliferative or proangiogenic stimuli were provided specifically by iPan injected
ALDHhi cells.
Clinical evidence suggests that strategies employing BM
or UCB stem cells can potentially benefit diabetic patients
via beta cell regenerative or immunomodulatory mechanisms [8, 9]. However, Haller and colleagues recently
reported that i.v. infusion of unfractionated UCB cells induced changes in regulatory T lymphocyte frequency but
failed to preserve C-peptide [9]. Although our study did not
directly address potential immunomodulatory mechanisms,
or the activation of putative islet-derived beta cell precursors
that may survive STZ toxicity [10], these experiments establish proof of concept that iPan delivery of purified ALDHhi
progenitor cells can formulate a regenerative niche that
impacts the behaviour and function of regenerating host islets.
Further investigation is warranted to elucidate the molecular
pathways activated in signal-receiving beta cells or beta cell
precursors during ALDHhi cell-stimulated islet regeneration,
as iPan delivery of UCB ALDHhi cells may represent a viable
strategy to ‘tip the balance’ in favour of islet expansion vs
destruction during diabetes.
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